1. Multi-arm Linker Platform：“Bioinorganic site-specific conjugation of multi-arm linkers to create pharmaceuticals with targeting and effector functions”J. Chin. Chem. Soc. 2026, 05 May. (https://doi.org/10.1002/jccs.70204) (榮獲 JCCS 邀稿撰寫 Review article，影響因子約 1.5)
2. TE-1146：“TE-1146, a novel anti-CD38-antibody-lenalidomide conjugate, demonstrates potent ex vivo anti-myeloma activity” Haematologica. 2026, 111(4), 1474-1477. (https://doi.org/10.3324/haematol.2025.288692) (影響因子為 7.9，在血液學領域約 75–120 種期刊中排名第 8 至第 10 )
3. TE-1146：“An antibody-drug conjugate for multiple myeloma prepared by multi-arm linkers” Adv. Sci. 2024, 2307852. (https://doi.org/10.1002/advs.202307852) (影響因子為 14.1，在奈米科學與奈米技術領域期刊中位居前 7–8%)
4. ARC：“Site-specific conjugation of 6 DOTA chelators to a CA19-9-targeting scFv-Fc antibody for imaging and therapy” J. Med. Chem. 2023, 66, 10604-10616. (https://doi.org/10.1021/acs.jmedchem.3c00753) (影響因子為 6.8，在藥物化學領域 72 種期刊中排名第 3)